Social needs screening and connection program for Metro Detroit cancer survivors
Official title: Addressing Social Determinants of Health (SDOH) Among Metro Detroit Cancer Survivors: A Pilot Feasibility Study (The Resource Ready Study)
Run by Barbara Ann Karmanos Cancer Institute · NCT06908629 · Data updated 2026-11-12
This project will test whether cancer survivors in Metro Detroit can complete a social needs screening and be connected to community resources for food and digital access.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | Barbara Ann Karmanos Cancer Institute Academic / other |
| Locations | 1 site (Detroit, Michigan) |
| Status | Recruiting |
| Started | September 3, 2024 |
| Main results expected | May 2027 |
| Study ends | May 2027 |
| Registry record updated | August 26, 2025 |
| Trial ID | NCT06908629 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with a past or current cancer diagnosis who live in Wayne, Oakland, or Macomb counties, are English proficient, and receive care at Karmanos outpatient clinics or are ROCS participants with prior food insecurity are ideal candidates.
✕Probably not a fit
Individuals who live outside the specified Metro Detroit counties, are not English proficient, or are not engaged with Karmanos care or the ROCS cohort are unlikely to qualify or benefit from this program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Participants with a past or current cancer diagnosis who live in Metro Detroit will complete a social needs screening either in person or by telephone. Responses will be translated into diagnosis codes that identify non-medical factors affecting health, and participants will be referred to community-based resources based on identified needs. The program includes brief interventions focused on food access and digital inclusion and follow-up telephone calls at 2, 4, 6, and 8 weeks to track referrals and outcomes. The team aims for at least an 80% completion rate and will use findings to refine referral procedures.
Why it matters
Potential benefit: If successful, more survivors could be identified and linked quickly to food, internet access, and other community supports that help them manage health after cancer.
How similar studies have gone: Other health-system programs that screen for social determinants and make referrals have successfully identified needs and increased resource connections, though long-term impact on clinical outcomes remains limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years or older * past or current cancer diagnosis * reside in metropolitan Detroit (Wayne, Oakland, Macomb counties) * English proficient * Actively receiving care through one of Karmano's Cancer Institute's outpatient clinics OR post treatment survivors in the Detroit Research on Cancer Survivors (ROCS) longitudinal cohort study who have reported past food insecurity and agreed to be contacted for further research Exclusion Criteria: * none
Where it's running
-
Karmanos Cancer Institute
Detroit, Michigan, United States Recruiting
Study contacts
- Study coordinator: Hayley S Thompson, Ph.D.
- Email: hayley.thompson@wayne.edu
- Phone: 313-576-9734
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
PD-L1-targeted PET probe to map PD-L1 in solid tumors
A PET tracer called 18F-F-PDL1-3 is being tested to see if it can detect PD-L1 expression in primary and metastatic tumors to help guide personalized treatment.
-
Pan-digestive tract cancer screening using blood methylation and fecal biomarkers
This study tests a combined blood and stool biomarker approach to screen for cancers throughout the digestive tract in adults awaiting endoscopy.
-
Brief Behavioral Activation for cancer survivors 65+
This study tests whether a short behavioral-activation therapy delivered by phone or video can help reduce depression and anxiety and improve well-being in English- or Spanish-speaking cancer survivors aged 65 and older.
-
New DLL3 PET/CT imaging for neuroendocrine tumors compared with standard scans
A new PET/CT scan using the 68Ga-DLL3 nanobody is being tested to see if it detects metastatic neuroendocrine tumors better than current scans in adults.
-
CTX-471 for NCAM-positive metastatic neuroendocrine tumors
A phase 2 trial is testing CTX-471 in adults with NCAM (CD56) positive metastatic neuroendocrine tumors that have progressed after standard therapy.
-
Smartphone app to help follow the 2024 KDIGO chronic kidney disease guidelines
This project will test whether a smartphone app helps young adults (ages 16–29) with chronic kidney disease follow the 2024 KDIGO guideline recommendations.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.